HOME >> BIOLOGY >> NEWS
Cost-effectiveness of treating multidrug-resistant tuberculosis

Researchers have made predictions as to how the tuberculosis (TB) epidemic in Peru might progress over the next 30 years, depending on what measures are used to fight it. They considered the five different approaches to treating drug-resistant TB that are open to the Peruvian health authorities.

TB is a growing problem worldwide. Most cases can be treated effectively with a standard treatment (known as 'DOTS', which stands for 'Directly Observed Therapy Short-Course') but an increasing number of cases are resistant to all the various 'first-line' treatment drugs; this is known as multi-drug resistant (MDR) TB. MDR-TB must be treated with 'second-line' drugs. There are several different options; for example, doctors could give second-line drugs whenever a first attempt at treatment has failed, or only use these drugs in cases where tests have confirmed MDR-TB to be the problem. MDR-TB cases could all be given the same standard treatment or, based on tests, each could have 'individualized' treatment.

The researchers used a method called 'modelling'. They performed calculations based on information already available about TB in Peru, where there are 120 new TB infections per 100,000 people every year and 4.5% of existing cases have MDR-TB. They concluded that use of second-line drugs would be cost-effective for Peru and that, despite the extra costs of individualized treatment, this is the best option. The results will be of interest in other developing countries. The researchers say, "In other settings, the attractiveness of strategies using second-line drugs will depend on TB incidence, MDR burden, and the available budget, but simulation results suggest that individualized regimens would be cost-effective in a wide range of situations". They also stress it is important for the standard first-line DOTS treatment to be made widely available.


'"/>

Contact: Andrew Hyde
ahyde@plos.org
44-122-346-3330
Public Library of Science
3-Jul-2006


Page: 1

Related biology news :

1. Cost-effectiveness study of three antimalarial drug combinations in Tanzania
2. Brain blood flow gives clues to treating depression
3. New strategy for treating allergic disorders
4. Developer of new method for treating bone defects wins WPI Entrepreneurship Award
5. UCF nanoparticle offers promise for treating glaucoma
6. Cisplatin is more effective than carboplatin for treating nonsmall cell lung cancer
7. 8 plants from South Africa may hold potential for treating high blood pressure
8. Arctic ice retreating more quickly than computer models project
9. Nanotechnology offers hope for treating spinal cord injuries, diabetes and Parkinsons disease
10. Discovery in plants suggests entirely new approach to treating human cancers
11. Preventing and treating lung cancer -- ESMO explores collaboration to fight cancer on all fronts

Post Your Comments:
(Date:6/16/2015)... , June 16, 2015  With the increasing ... security remains a top concern. The recent compromise of ... the need for strong authentication within government agencies. ... a biometric one-time password (OTP) authenticator, has been submitted ... (FIPS) 140-2 Level 3 validation for tamper proofing. ...
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue ... amount to at least 340 MSEK to that it will ... in market growth and orders received the revenue guidance for ... for 2015 will exceed 1,500 MSEK to an updated guidance ... Due to receipt of orders of touch fingerprint ...
(Date:6/15/2015)... , June 15, 2015 A new ... Telstra reveals the majority of US consumers using mobile banking ... biometrics, such as fingerprint and voiceprint, instead of having to ... According to Telstra,s " Mobile Identity   -   The ... report, with smartphones now the primary channel used by Gen ...
Breaking Biology News(10 mins):Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
(Date:7/1/2015)... PARIS , July 1, 2015 ... key developer of biotech crops, today announce a ... generations of insect control traits. "Growers ... the realities of advancing insect resistance. We are ... insect control technology with Genective,s capability in developing ...
(Date:7/1/2015)... ... ... The next-generation sequencing (NGS) clinical market is poised for huge growth as it prepares ... in its new report that the market drivers of this vibrant industry include increased ... diagnostics as part of a molecular diagnostics trend. , The global market is forecast ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus Pharmaceuticals, ... development of groundbreaking drugs to treat neurodegenerative diseases ... that Robert G. Miller , M.D., Director of ... Health,s California Pacific Medical Center in San Francisco, has ... for $1.5 million to help fund a Phase ...
(Date:7/1/2015)... July 1, 2015 Isagenix International, a leading ... three Gold, three Silver, and three Bronze Stevie® Awards ... in Chicago this month.The ... business awards program in the U.S. ... strength in developing leaders, cultivating talent, creating a unified ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3
Cached News: